VANCOUVER, BC – Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural… Read More
Simon Fraser University is Canada’s top university for innovation and second for industrial application according to the World University Rankings for Innovation (WURI) 2024 rankings. This marks the fourth consecutive… Read More
PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, IL – AbbVie (NYSE: ABBV)… Read More
SAN DIEGO, CA – Horizon Health Network (Horizon), through an innovative partnership with Roche Canada, the New Brunswick Extra-Mural Program, the Government of New Brunswick and ResearchNB, and with the support of… Read More
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible… Read More
